NEPHROS INC
Close on Oct 19, 2026
- Market cap
- $40.89M
- P/E (TTM)
- 23.0
- Dividend yield
- –
About Nephros
Surgical & Medical Instruments & Apparatus, SIC 3841
Nephros, Inc. develops and commercializes point-of-use water filtration products for medical and commercial applications. The company operates two medical filtration product lines: infection control microfilters and ultrafilters that remove bacteria, viruses, and endotoxins, and dialysis ultrafilters that purify water and bicarbonate concentrates used in hemodialysis treatments. Its commercial offerings feature carbon-based and carbon-free filters designed to eliminate taste, odor, lead, cysts, scale, and per- and polyfluoroalkyl substances. Nephros primarily serves hospitals, healthcare facilities, dialysis clinics, and foodservice and hospitality establishments, alongside laboratories, manufacturing plants, aviation environments, and government facilities.
The company markets its products in the United States and international markets using an internal direct sales force and distributors, including value-added resellers. It maintains an office in Whippany, New Jersey, and operates a commercial filter manufacturing site alongside its corporate headquarters in South Orange, New Jersey. Medical filtration products are sourced through an exclusive supply partner located in Italy.
Summary of the business section of Nephros's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NEPHROS INC
- Founded
- 1997
- Headquarters
- South Orange, NJ
- Address
- 380 Lackawanna Place 07079
- Phone
- (201) 343-5202
- Website
- nephros.com
- Employees
- 36, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Tewksbury, Massachusetts
Stock & identifiers
- Ticker
- NEPH
- Exchange
- Nasdaq
- Shares outstanding
- 11M, Aug 7, 2026
- Public float
- $27.32M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-9 reverse, Aug 7, 2019; 1-for-9 reverse, Jul 10, 2019; 1-for-20 reverse, Mar 17, 2011
- SEC CIK
- 1196298
- CUSIP
- 640671400
- ISIN
- US6406714005
- LEI
- 549300TLN1G9WX00KA57
- EIN
- 13-3971809
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert R. Banks Jr. | President and CEO | 190,000 |
| Judy Krandel | Chief Financial Officer | 68,861 |
| Holdings LLC Amron | Director | 187,005 |
| Arthur H. Amron | Director | 140,874 |
| Lisa Marie Nettis | Director | 1,622 |
| Oliver J. Spandow | Director | 122,881 |
| Alisa Lask | Director | 48,629 |
| Joseph Michael Harris | Director | 17,693 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Second Peo | $410.17K | -$175.73K | $148.70K | $25 | – |
| FY2023 First Peo | $545.55K | $544.40K | $167.57K | $40 | – |
| FY2023 Second Peo | $694.97K | $1.29M | $167.57K | $40 | – |
| FY2022 First Peo | $334.75K | -$36.68K | $212.44K | $14 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we employed a total of 36 full-time employees, including 12 employed in sales/marketing/customer support, 17 in”
Corporate history
Events identified from SEC filings